Kate Dawson: The Future Looks Bright For Multiple Sclerosis Treatment for Biogen

Video

With multiple medications approved to treat multiple sclerosis there is more work being done to help a larger patient population through the course of disease treatment.

With multiple medications approved to treat multiple sclerosis there is more work being done to help a larger patient population through the course of disease treatment.

While there is work being done to develop new treatments, Kate Dawson, MD, from Biogen said the company is working on new potential treatment methods in addition to finding new applications for its medications on the market today. Dawson, speaking at the annual ECTRIMS meeting in London said they are looking specifically at remylination in addition to other potential alternatives.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.